Here are what the editors at HealthDay consider to be the most important developments in Nephrology for May 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Insulin Receptor Substrate 1 Variant Linked to GFR
THURSDAY, May 31 (HealthDay News) -- A variant of the human insulin receptor substrate 1 (IRS1) gene, which plays an important role in modulating tissue response to insulin, is significantly associated with glomerular filtration rate (GFR), according to a study published online May 22 in Diabetes.
Abstract
Full Text (subscription or payment may be required)
Intensive Glucose Control Helps Surrogate Renal End Points
THURSDAY, May 31 (HealthDay News) -- Intensive glucose therapy significantly reduces microalbuminuria and macroalbuminuria in adults with type 2 diabetes, but does not improve clinical renal outcomes, according to a study published in the May 28 issue of the Archives of Internal Medicine.
Abstract
Full Text
Editorial
Post-Transplant, eGFR Impacts Cardio Risk Independently
WEDNESDAY, May 30 (HealthDay News) -- In stable kidney transplant recipients, kidney function, as determined by estimated glomerular filtration rate (eGFR), is independently associated with cardiovascular (CVD) events and death, according to research published online May 17 in the American Journal of Transplantation.
Abstract
Full Text (subscription or payment may be required)
Peritonitis Ups Odds of Mortality in Peritoneal Dialysis Patients
FRIDAY, May 25 (HealthDay News) -- Among patients who die while on peritoneal dialysis, peritonitis is associated with mortality, with the highest odds for peritonitis in the 30 days before death, according to a study published online May 24 in the Journal of the American Society of Nephrology.
Abstract
Full Text (subscription or payment may be required)
Rituximab Little Use in Resistant Idiopathic Nephrotic Syndrome
FRIDAY, May 11 (HealthDay News) -- The anti-CD20 monoclonal antibody, rituximab, added to prednisone and calcineurin inhibitors, does not provide any additional benefit in terms of reduced proteinuria in the treatment of children with resistant idiopathic nephrotic syndrome (INS), according a study published online May 10 in the Journal of the American Society of Nephrology.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Newer Model Better Identifies eGFR-Related Risks
TUESDAY, May 8 (HealthDay News) -- The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation more accurately identifies the risk implications of estimated glomerular filtration rate (eGFR) than the Modification of Diet in Renal Disease (MDRD) Study equation, according to research published in the May 9 issue of the Journal of the American Medical Association.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
CMS Policy Helping Hospitals to Prevent Targeted Infections
FRIDAY, May 4 (HealthDay News) -- Hospitals seem to be paying greater attention to preventing targeted health care-associated infections (HAIs) as a result of the Centers for Medicare and Medicaid Services (CMS) nonpayment policy, according to a study published in the May issue of the American Journal of Infection Control.
Abstract
Full Text
Lupus Nephritis Screening and Management Guidelines Issued
FRIDAY, May 4 (HealthDay News) -- The American College of Rheumatology has produced new guidelines for the screening, treatment, and management of lupus nephritis; the guidelines have been published in the June issue of Arthritis Care & Research.
Abstract
Full Text (subscription or payment may be required)
Methodological Heterogeneity Seen in Clinical Trials
TUESDAY, May 1 (HealthDay News) -- Clinical studies registered with ClinicalTrials.gov from 2007 and 2010 are predominately small, single-center trials and contain significant heterogeneity in methodology, according to a study published in the May 2 issue of the Journal of the American Medical Association.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
In CKD, Fish Oil Doesn't Up Hemodialysis Graft Patency
TUESDAY, May 1 (HealthDay News) -- For patients with stage 5 chronic kidney disease, fish oil does not improve synthetic hemodialysis graft patency, according to a study published in the May 2 issue of the Journal of the American Medical Association.
Abstract
Full Text
Editorial (subscription or payment may be required)
|
